Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Evaluate the Effect of Solifenacin and Mirabegron on the Tamsulosin Hydrochloride (HCl) Concentrations in Blood in Healthy Male Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02169713
Recruitment Status : Completed
First Posted : June 23, 2014
Last Update Posted : August 29, 2014
Sponsor:
Information provided by (Responsible Party):
Astellas Pharma Inc ( Astellas Pharma Europe B.V. )

Brief Summary:
The purpose of this study is to evaluate the effect of solifenacin and mirabegron on the concentrations of tamsulosin HCl after combined dosing. This study will also evaluate the safety and tolerability of the combined administration of solifenacin, mirabegron and tamsulosin HCl.

Condition or disease Intervention/treatment Phase
Healthy Subjects Pharmacokinetics Drug-Drug Interaction (DDI) Drug: Mirabegron Drug: Solifenacin succinate Drug: Tamsulosin HCl Drug: Placebo Phase 1

Detailed Description:
This study is comprised of two study sequences with 2 investigational periods in each sequence. There will be a wash-out period between each investigational period. Patients will be admitted to the clinic until discharged after each investigational period.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Basic Science
Official Title: A Phase 1 Study to Evaluate the Effect of Steady State Solifenacin and Mirabegron on the Steady State Pharmacokinetics of Tamsulosin HCl in Healthy Male Subjects
Study Start Date : May 2014
Actual Primary Completion Date : August 2014
Actual Study Completion Date : August 2014

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Treatment Sequence 1
Tamsulosin HCl alone (with matching placebo for solifenacin and mirabegron) then followed by tamsulosin HCl with solifenacin and mirabegron
Drug: Mirabegron
Oral
Other Names:
  • Myrbetriq
  • Betmiga
  • Betanis

Drug: Solifenacin succinate
Oral
Other Names:
  • solifenacin
  • Vesikur
  • Vesicare

Drug: Tamsulosin HCl
Oral
Other Name: Flomax

Drug: Placebo
Oral

Experimental: Treatment Sequence 2
Tamsulosin HCl with solifenacin and mirabegron then followed by tamsulosin HCl alone (with matching placebo for solifenacin and mirabegron)
Drug: Mirabegron
Oral
Other Names:
  • Myrbetriq
  • Betmiga
  • Betanis

Drug: Solifenacin succinate
Oral
Other Names:
  • solifenacin
  • Vesikur
  • Vesicare

Drug: Tamsulosin HCl
Oral
Other Name: Flomax

Drug: Placebo
Oral




Primary Outcome Measures :
  1. Pharmacokinetic parameter for tamsulosin HCl (plasma) in the absence and presence of solifenacin and mirabegron: Cmax [ Time Frame: Day 14 in each investigational period ]
    Maximum concentration (Cmax)

  2. Pharmacokinetic parameter for tamsulosin HCl (plasma) in the absence and presence of solifenacin and mirabegron: AUCtau [ Time Frame: Day 14 in each investigational period ]
    Area under the curve over a dosing interval (AUCtau)


Secondary Outcome Measures :
  1. Pharmacokinetic parameter for tamsulosin HCl (plasma): Ctrough [ Time Frame: Days 11, 12 and 13 in each investigational period ]
    Concentration immediately prior to dosing at multiple dosing (Ctrough)

  2. Pharmacokinetic parameter for tamsulosin HCl (plasma): tmax, CL/F, PTR [ Time Frame: Day 14 in each investigational period ]
    Time after dosing when Cmax occurs (tmax), apparent total systemic clearance after single or multiple extra-vascular dosing (CL/F), Peak-through ratio (PTR)

  3. Pharmacokinetic parameter for solifenacin and mirabegron (plasma): Ctrough [ Time Frame: Days 11, 12 and 13 in each investigational period ]
    Concentration immediately prior to dosing at multiple dosing (Ctrough)

  4. Pharmacokinetic parameter for solifenacin and mirabegron (plasma): Cmax, AUCtau, tmax, CL/F [ Time Frame: Day 14 in each investigational period ]
    Maximum concentration (Cmax), Area under the curve over a dosing interval (AUCtau), Time after dosing when Cmax occurs (tmax), apparent total systemic clearance after single or multiple extra-vascular dosing (CL/F)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   45 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Subject has a body mass index range of 18.5 to 30.0 kg/m2, inclusive. The subject weighs at least 50 kg [screening].
  • Subject and their female spouse/partners who are of childbearing potential must be using a highly effective form of contraception consisting of 2 forms of birth control (one of which must be a barrier method) starting at screening and continue throughout the clinical study period and for 90 days after the final study drug administration.
  • Subject must not donate sperm starting at screening and throughout the clinical study period and for 90 days after the final study drug administration.
  • Subject agrees not to participate in another interventional study while participation in the present clinical study, defined as signing the informed consent form until completion of the last clinical study visit.

Exclusion Criteria:

  • Subject has a known or suspected hypersensitivity to solifenacin succinate, mirabegron, tamsulosin HCl or any components of the formulations used including sulfa allergies.
  • Subject has any of the liver function tests (aspartate aminotransferase [AST], alanine aminotransferase [ALT], alkaline phosphatase, gamma-glutamyl transferase and/or total bilirubin [TBL]) above 1.5 of the upper limit of normal (ULN). In such a case the assessment may be repeated once [day-1].
  • Subject has any clinically significant history of allergic conditions.
  • Subject has any history or evidence of any clinically significant cardiovascular, gastrointestinal, endocrine, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal and/or other major disease or malignancy, as judged by the Medical Investigator.
  • Subject has/had febrile illness or symptomatic, viral, bacterial (including upper respiratory infection), or fungal (non-cutaneous) infection within 1 week prior to day -2 (admission day).
  • Subject has any clinically significant abnormality following the Investigator's review of the physical examination, electrocardiogram (ECG) and protocol-defined clinical laboratory tests at screening or day -1.
  • Subject has a mean pulse rate of < 50 or > 90 bpm; mean systolic BP < 90 mmHg or > 140 mmHg; mean diastolic BP < 60 mmHg or > 90 mmHg at day -1 (vital sign measurements taken in triplicate after subject has been resting in supine position for 10 min; pulse rate will be measured automatically).
  • Subject has a mean QTc(F) interval of > 430 ms (> 450 for subjects aged 65 and above) at day -1. If the mean QTc(F) exceeds the limits above, 1 additional triplicate ECG can be taken.
  • Subject has any clinical significant history of or risk of urinary retention, severe gastrointestinal condition (including toxic megacolon), myasthenia gravis or narrow-angle glaucoma, orthostatic hypotension.
  • Subject has a history of unexplained syncope, cardiac arrest, unexplained cardiac arrhythmias or torsade de pointes, structural heart disease, or a family history of Long QT Syndrome.
  • Subject uses any prescribed or non-prescribed drugs (including vitamins, natural and herbal remedies [e.g., St. John's Wort]) in the 2 weeks prior to study drug administration, except for occasional use of paracetamol (up to 2 g/day).
  • Subject has a history of smoking more than 10 cigarettes (or equivalent amount of tobacco) per day within 3 months prior to admission to the clinical unit on day -2.
  • Subject has a history of drinking more than 21 units of alcohol per week (1 unit = 10 g pure alcohol = 250 mL of beer [5%] or 35 mL of spirits [35%] or 100 mL of wine [12%]) within 3 months prior to admission to the clinical unit on day -2.
  • Subject has consumed grapefruit (more than 3 x 200 mL) or marmalade (more than 3 times), star fruit, Seville oranges or Seville orange juice-containing products in the week prior to admission to the clinical unit until end of study visit (ESV), as reported by the subject.
  • Subject uses any drugs of abuse within 3 months prior to admission to the clinical unit.
  • Subject uses any inducer of metabolism (e.g., barbiturates, rifampin) in the 3 months prior to admission to the clinical unit regularly.
  • Subject has significant blood loss, donated 1 unit (500 mL) of blood or more, or received a transfusion of any blood or blood products within 60 days or donated plasma within 7 days prior to clinical unit admission on day -2.
  • Subject has a positive serology test for hepatitis B surface antigen, hepatitis B core antibodies, hepatitis A virus antibodies (Immunoglobulin M), hepatitis C virus antibodies or human immunodeficiency virus 1 + 2 antibodies.
  • Subject participated in any clinical study or has been treated with any investigational drugs within 28 days prior to screening.
  • Subject is a vulnerable subject (e.g., subject kept in detention).
  • Subject is an employee of the Astellas Group or Contract Research Organization involved in the clinical study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02169713


Locations
Layout table for location information
Germany
Parexel International GmbH
Berlin, Germany, 14050
Sponsors and Collaborators
Astellas Pharma Europe B.V.
Investigators
Layout table for investigator information
Study Director: Clinical Research Physician Astellas Pharma Europe B.V.
Layout table for additonal information
Responsible Party: Astellas Pharma Europe B.V.
ClinicalTrials.gov Identifier: NCT02169713    
Other Study ID Numbers: 178-CL-109
2013-004230-15 ( EudraCT Number )
First Posted: June 23, 2014    Key Record Dates
Last Update Posted: August 29, 2014
Last Verified: August 2014
Keywords provided by Astellas Pharma Inc ( Astellas Pharma Europe B.V. ):
Healthy subjects
Mirabegron
Solifenacin
Tamsulosin HCl
Additional relevant MeSH terms:
Layout table for MeSH terms
Tamsulosin
Solifenacin Succinate
Mirabegron
Adrenergic alpha-1 Receptor Antagonists
Adrenergic alpha-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Urological Agents
Muscarinic Antagonists
Cholinergic Antagonists
Cholinergic Agents
Adrenergic beta-3 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists